KOSDAQBiotech & Pharma182400

NKGen Biotech Korea

₩3,670 0.00%2026-11-18 close
Market Cap
₩265.5B
Turnover
₩0
Volume
0 shares
Shares out.
72.3M
PER
—
PBR
47.1×
EPS
-₩26
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses narrow and quarterly profit returns, recovery still in progress

Operating losses have shrunk sharply since 2023 and operating profit turned positive in Q2 2026, but revenue fell for three straight years and the company has posted net losses attributable to controlling shareholders over the last four quarters, so the durability of the recovery is still unproven.

  1. 1

    Revenue has declined for three consecutive years from 2023 to 2025, reaching KRW 7.86 billion in 2025 (based on filed results).

  2. 2

    The operating loss narrowed from KRW 67.3 billion in 2023 to KRW 2.53 billion in 2025, and quarterly operating profit turned positive in Q2 2026 (KRW 186 million) before falling to KRW 48.66 million in Q3 2026.

  3. 3

    Q3 2026 revenue of KRW 2.34 billion extended a two-quarter rise, but the company returned to a net loss attributable to controlling shareholders of KRW 316 million in the same quarter.

  4. 4

    The largest shareholder, NKGen Biotech, Inc., holds 64.14%, and a share-pledged loan agreement was disclosed in April 2026.

  5. 5

    Overseas test distribution through Thailand's MEDEZE Group and health food sales point to diversification, but their contribution to reported results is not yet visible in the filings.

02

Business structure

NKGen Biotech Korea was established in 2002 to manufacture research reagents and conduct R&D, and it listed on KOSDAQ on October 23, 2015. The business spans immunodiagnostic kits, NK cell immunotherapy development, and health functional food sales.

Based on the revenue mix shown on a securities information page, the NK Vue KIT accounts for the largest share at 47.60%, followed by research reagents at 33.82%, NK365 and related products at 11.60%, research services at 6.55%, and other services at 0.41%.

The NK Vue KIT is reported to be used at more than 2,400 medical institutions, and its sales declined after the product moved to non-covered treatment in 2024. Overseas, Thailand's MEDEZE Group, a listed cell therapy company, holds a network of more than 260 hospital partners.

MEDEZE previously imported the company's test kits for its own use and now plans to extend testing to partner hospitals and clinics. The health functional food Slim by 365 sold about 200,000 initial capsules within roughly six months of launch, and a second batch has entered production.

On the therapy side, the company develops immune cell therapies on its SuperNK platform, targeting cancer and Alzheimer's disease; SNK01 has FDA Fast Track designation, and SNK02 has IND clearance for solid tumors including gastric cancer.

A December 2025 report said immune cell therapies still need considerable time before commercialization, so near-term results depend mainly on diagnostics, reagents, and health food sales.

The largest shareholder, NKGen Biotech, Inc., holds 64.14%, so decisions at the US parent also bear on the direction of the Korean company.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2.2B₩43,793,5852.0%
2025Q4₩2.2B-₩1.3B−61.0%
2026Q1₩1.6B-₩1.2B−76.6%
2026Q2₩2.1B₩200M8.7%
2026Q3₩2.3B₩48,661,9472.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩11.3B-₩49.7B-₩53.5B−440.9%−62.3%103.9%
2023₩9.9B-₩67.3B-₩153.4B−676.8%—−683.1%
2024₩8.8B-₩4.1B-₩36.9B−46.2%—−191.5%
2025₩7.9B-₩2.5B-₩7.3B−32.2%−103.5%101.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue fell from KRW 11.3 billion in 2022 to KRW 9.95 billion in 2023 (down 11.7% year on year), KRW 8.8 billion in 2024 (down 11.5%), and KRW 7.86 billion in 2025 (down 10.7%).

Revenue has declined for three consecutive years from 2023 to 2025, with 2022 the largest year and 2025 the smallest in the 2022–2025 period.

The operating loss widened from KRW 49.7 billion in 2022 to KRW 67.3 billion in 2023, then narrowed to KRW 4.06 billion in 2024 and KRW 2.53 billion in 2025, marking four consecutive years of losses. The operating margin moved from -440.9% in 2022 to -676.8% in 2023, then improved to -46.2% in 2024 and -32.2% in 2025.

The net loss attributable to controlling shareholders was KRW 53.5 billion in 2022, KRW 153.4 billion in 2023, KRW 36.9 billion in 2024, and KRW 7.34 billion in 2025. The net loss including non-controlling interests was KRW 55.6 billion in 2022 and matched the controlling-shareholder figure from 2023 onward.

At the end of 2025, total equity was KRW 7.1 billion, equity attributable to controlling shareholders was KRW 7.1 billion, and total liabilities were KRW 7.2 billion, giving a debt ratio of 101.5%. The negative debt ratios shown for 2023 and 2024 reflect negative total equity in those years.

Operating cash flow was -KRW 38.1 billion in 2022, -KRW 35.1 billion in 2023, -KRW 1.26 billion in 2024, and -KRW 3.2 billion in 2025. Quarterly revenue bottomed at KRW 1.57 billion in Q1 2026, down 28.8% from the prior quarter, and then rose to KRW 2.14 billion in Q2 and KRW 2.34 billion in Q3, a two-quarter increase.

Operating profit of KRW 43.79 million in Q3 2025 turned into an operating loss of KRW 1.35 billion in Q4 2025, then a KRW 186 million operating profit in Q2 2026, and KRW 48.66 million in Q3 2026, down 73.8% from the prior quarter.

The net loss attributable to controlling shareholders was KRW 316 million in Q3 2026, and the last four quarters total a net loss attributable to controlling shareholders of KRW 1.85 billion.

Quarters with positive operating profit still showed controlling-shareholder net losses, which suggests non-operating items are driving quarterly results; the breakdown should be checked in the periodic report notes.

05

Industry analysis

The company handles both NK cell-based immunotherapy and NK cell activity diagnostic kits, so the therapy market and the diagnostics market should be considered separately.

Industry classifications differ by source: one lists the company under KOSDAQ pharmaceuticals, another under life science tools and services, and Alphasquare compares it within the medical devices and supplies group of 97 companies, so industry comparisons depend on the benchmark chosen.

In that Alphasquare comparison, the operating margin is higher than the industry average but ranks 68th among the 97 companies. On the diagnostic side, the NK immune test measures NK cell activity from a blood sample, and the company plans to use it to track immune status before and after cell therapy.

On overseas demand, company officials said cell therapy is growing actively in Thailand and that NK activity testing could become an important monitoring tool there. The partner MEDEZE Group holds a Thai cell bank standard certification and is the only private company in Thailand's ATMP sandbox.

Immunotherapy commercialization still requires clinical and regulatory steps, so the pace of competing trials shapes the company's position.

The diagnostic kits serve two demand pools, domestic hospital checkup centers and overseas hospitals, and which of these demand pools grows will matter more for results than the broader cycle.

06

Outlook

The company's most visible growth lever is expanding overseas test supply. MEDEZE Group said it plans to expand test adoption to partner hospitals and clinics in Thailand that use its NK cell therapy program.

However, the scale of the expansion will depend on whether individual medical institutions adopt the test, so the size is hard to gauge yet. For health functional foods, the company is moving beyond online-mall sales toward more distribution channels after its first batch sold out.

On the therapy side, the FDA Fast Track designation for SNK01 may speed development, but designation alone is not approval, so the commercialization timing cannot be pinned down until follow-up clinical data are available.

On the financing side, the largest shareholder signed a share-pledged loan agreement on April 22, 2026, covering about 46.4 million shares with a loan amount of roughly KRW 39 billion, and this structure links the parent's funding position to governance at the Korean company.

The valuation date for the parent's forward purchase agreement falls on December 31, 2026. Official figures for the 2026 full year will come with the 2026 annual report, and the next checkpoints are whether quarterly profit holds and whether revenue growth extends beyond the two-quarter rise into a sustained recovery.

07

Valuation

PER
—
PBR
47.1×
ROE
-30.9%
EPS
-₩26
BPS
₩78
Dividend per share
₩0

The current share price is hard to explain with earnings-based multiples. Because the last four quarters show a net loss, the P/E ratio cannot be calculated, and the share price sits in a range where the price-to-book ratio carries most of the explanatory weight, reflecting a large premium over net asset value.

That structure suggests the market is pricing in a meaningful share of the growth from the pipeline and overseas testing. The dividend yield is effectively zero, so shareholder returns through dividends are not visible in the current structure.

The sharp narrowing of losses and the Q2 2026 quarterly profit point toward earnings recovery, but the renewed net loss in Q3 2026 means earnings-based multiples will take time to stabilize.

A debt ratio of 101.5%, with total liabilities roughly equal to total equity, is another metric to read alongside the share price.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Narrowing losses and quarterly profit

The operating loss narrowed from KRW 67.3 billion in 2023 to KRW 2.53 billion in 2025. Operating profit of KRW 186 million in Q2 2026 marked a return to profit. If the narrowing continues, it would support a gradual improvement in the income structure.

Two straight quarters of revenue growth after a trough

Revenue bottomed at KRW 1.57 billion in Q1 2026 and rose to KRW 2.14 billion in Q2 and KRW 2.34 billion in Q3. Q3 revenue was up 6.0% year on year. If the trend holds in Q4, it could signal an end to the annual revenue decline.

Pipeline and overseas distribution expansion

SNK01 has FDA Fast Track designation and SNK02 has IND clearance. The MEDEZE network of more than 260 hospitals in Thailand could widen test supply. The sell-out of the first health food batch shows a consumer channel beyond the diagnostics business.

09

Bear factors

Three straight years of revenue decline

Revenue fell from KRW 11.3 billion in 2022 to KRW 9.95 billion in 2023, KRW 8.8 billion in 2024, and KRW 7.86 billion in 2025. The decline has run for three consecutive years. The recovery since the Q1 2026 trough remains small in size.

Thin equity and renewed quarterly losses

At the end of 2025, total equity was KRW 7.1 billion and total liabilities were KRW 7.2 billion, giving a debt ratio of 101.5%. Q3 2026 returned to a controlling-shareholder net loss of KRW 316 million.

Parent-level financial strain and a low free float

The largest shareholder holds 64.14%, and the free float ratio is 35.82%. A loan secured by the parent's shares was disclosed in April 2026. A February 2026 report on the parent, which trades over the counter in the US, said its total debt far exceeded its market capitalization.

10

Risk factors

Controlling shareholder and governance

The 64.14% stake and the pledged loan structure mean the parent's funding position could affect decisions and share liquidity at the Korean company. A low free float can also make trading more sensitive to price moves. Parent-level contract dates should be tracked alongside company filings.

Timing of therapy commercialization

Assessments say immune cell therapies still need considerable time before commercialization. Fast Track designation and IND clearance mark stages of clinical development, not approval. Results below expectations could significantly change how the pipeline is valued.

Earnings volatility and audit history

Quarterly operating results have alternated between profit and loss, and profitable quarters still showed controlling-shareholder net losses. The 2023 audit report carried a disclaimer of opinion from the external auditor, which led to a delisting decision and an injunction request. Follow-up outcomes of that history should be checked through company filings.

11

What to watch next

  1. December 31, 2026

    The valuation date for the largest shareholder's forward purchase agreement. It is a point to gauge how the parent's funding conditions could affect the ownership structure of the Korean company.

  2. End of December 2026 (Q4 2026 close)

    Whether expanded test supply through the MEDEZE hospital network shows up in Q4 revenue. The key questions are whether the two-quarter revenue rise continues and whether the Q3 drop in operating profit repeats.

  3. March 2027 (the 2025 annual report was filed on March 24, 2026)

    The 2026 annual report will provide official full-year revenue, operating margin, net loss attributable to controlling shareholders, and debt ratio. It is the point to check whether the four-year loss streak continues and whether quarterly profits carry into the annual results.

12

Overall view

On filed results, revenue has declined for three consecutive years from 2023, while the operating loss narrowed sharply from KRW 67.3 billion in 2023 to KRW 2.53 billion in 2025.

Operating profit of KRW 186 million in Q2 2026 marked a turn to profit, but Q3 2026 operating profit fell to KRW 48.66 million and the controlling-shareholder net loss returned at KRW 316 million. The last four quarters total a controlling-shareholder net loss of KRW 1.85 billion.

On the balance sheet, total liabilities of KRW 7.2 billion at the end of 2025 are close in size to total equity of KRW 7.1 billion, giving a debt ratio of 101.5%.

On the business side, diagnostic kits are being supplemented by a sold-out health food batch and expanding test supply through MEDEZE's hospital network, but the overseas volume depends on individual hospital adoption.

The SNK01 and SNK02 programs are at FDA designation and IND clearance stages, so commercialization remains distant. The largest shareholder's 64.14% stake and its pledged loan structure remain governance variables for the Korean company. The next checkpoints are the Q4 2026 trend and the operating margin in the March 2027 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. m.news.nate.com
  2. comp.wisereport.co.kr
  3. fnnews.com
  4. ebn.co.kr
  5. etoday.co.kr
  6. fnnews.com
  7. stockplus.com
  8. alphasquare.co.kr
  9. medicopharma.co.kr
  10. ksdaily.co.kr
  11. supple.kr
  12. news.nate.com
  13. newspim.com
  14. digitaltoday.co.kr
  15. sentv.co.kr
  16. kr.investing.com
  17. m.sedaily.com
  18. thevc.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis